Was thinking about this earlier, what are the success criteria. Even if it turned out there was 50% less dox that the heart (and rest of the body) would be exposed to. Is that still something they would move forward with?
From the mouse, and canine models they are seeking a massive improvement from 1 to 1 to 1 to 18 so is there a criteria where it would have to be equivalent?
Would be absolutely amazing if avacta could give these patients an increased survival rate. I'm guessing the stage they are at thier bodies are already badly affected by the side effects of dox.
And of course that isn't the aim of the trial but what a result of the tumours were to decrease in size.
As it's so predictable and I've not had much luck before I did dabble this morning sold 5k early doors and bought back at 116.5 proper wannabe wynbore....
A whole 110 shares up :) can't wait till they are 50 quid in June